Ontology highlight
ABSTRACT:
SUBMITTER: Kugel CH
PROVIDER: S-EPMC4212018 | biostudies-literature | 2014 Nov
REPOSITORIES: biostudies-literature
Kugel Curtis H CH Aplin Andrew E AE
Pigment cell & melanoma research 20140606 6
The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma opened the door to new treatment options, which have resulted in significantly better patient outcomes. Treatments such as the FDA-approved RAF inhibitor vemurafenib and the more recently approved dabrafenib and trametinib combination therapy are designed to target the ERK1/2 pathway. Initial success in targeting this pathway is evidenced by the high percentage of melanoma patients who undergo tumor remission. ...[more]